Recombinant Human Prourokinase for Injection (rhPro-UK)

DRUG3 trials

Sponsors

Beijing Tiantan Hospital, The First Affiliated Hospital of Anhui Medical University, Second Affiliated Hospital, Zhejiang University, School of Medicine

Conditions

Acute Ischemic StrokeIschemic StrokeMildThrombosis

Phase 3

ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)

CompletedNCT05507645

Beijing Tiantan HospitalIschemic Stroke, Mild, Thrombosis

Start: 2022-11-15End: 2024-06-17Updated: 2024-09-05

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

RecruitingNCT07776873

The First Affiliated Hospital of Anhui Medical UniversityAcute Ischemic Stroke

Start: 2026-10-06End: 2029-06-30Target: 616Updated: 2026-10-07

Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence

Not yet recruitingNCT07901842

Second Affiliated Hospital, Zhejiang University, School of MedicineAcute Ischemic Stroke

Start: 2026-12-01End: 2030-06-01Target: 826Updated: 2026-10-28

Related Papers

Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke

JAMA Neurology2025-01-2115 citations

Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial.

2024-12-303 citations